
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary techno... Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAAR, T cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CAAR T cell product candidate was designed based on the clinically validated and commercially approved Chimeric Antigen Receptor, or CAR, T cell technology that is marketed for the treatment of B cell cancers. Show more
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1492 | -8.33519553073 | 1.79 | 1.85 | 1.64 | 746206 | 1.72844283 | CS |
4 | -0.3192 | -16.2857142857 | 1.96 | 2.03 | 1.59 | 817375 | 1.80144526 | CS |
12 | -0.6192 | -27.3982300885 | 2.26 | 2.8895 | 1.59 | 1206113 | 2.24578098 | CS |
26 | -2.3692 | -59.0822942643 | 4.01 | 5.46 | 1.59 | 1802246 | 2.9825284 | CS |
52 | -16.0692 | -90.7351778656 | 17.71 | 19.04 | 1.59 | 1495889 | 5.51909492 | CS |
156 | -0.6292 | -27.718061674 | 2.27 | 26.35 | 0.59 | 1043603 | 7.74145303 | CS |
260 | -5.3092 | -76.3913669065 | 6.95 | 26.35 | 0.59 | 697996 | 7.74906152 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales